TESARO Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
317.00
58,018.00
223,326.00
Cost of Goods Sold (COGS) incl. D&A
179.00
349.00
1,037.00
4,316.00
50,667.00
Gross Income
179.00
349.00
720.00
53,702.00
172,659.00
SG&A Expense
90,326.00
142,011.00
233,322.00
392,464.00
642,178.00
EBIT
90,505.00
142,360.00
234,042.00
-
469,519.00
Unusual Expense
1,940.00
24,900.00
2,000.00
18,940.00
10,000.00
Non Operating Income/Expense
-
-
-
-
328.00
Interest Expense
-
3,776.00
15,414.00
16,487.00
19,758.00
Pretax Income
92,362.00
171,012.00
251,408.00
372,749.00
494,802.00
Income Tax
-
-
-
1,475.00
1,324.00
Consolidated Net Income
92,362.00
171,012.00
251,408.00
374,224.00
496,126.00
Net Income
92,362.00
171,012.00
251,408.00
374,224.00
496,126.00
Net Income After Extraordinaries
92,362.00
171,012.00
251,408.00
374,224.00
496,126.00
Net Income Available to Common
92,362.00
171,012.00
251,408.00
374,224.00
496,126.00
EPS (Basic)
2.93
4.79
6.38
7.85
9.17
Basic Shares Outstanding
31,559.00
35,739.00
39,387.00
47,652.00
54,080.00
EPS (Diluted)
2.93
4.79
6.38
7.85
9.17
Diluted Shares Outstanding
31,559.00
35,739.00
39,387.00
47,652.00
54,080.00
EBITDA
90,326.00
142,011.00
233,005.00
335,649.00
459,989.00
Non-Operating Interest Income
83.00
24.00
48.00
1,440.00
4,147.00

About TESARO

View Profile
Address
1000 Winter Street
Waltham Massachusetts 02451
United States
Employees -
Website http://www.tesarobio.com
Updated 09/14/2018
TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib. The company was founded by Leon Moulder, Jr.